Regulatory Revisions, Cut Backs At Big Pharma, Provide Spark For China Innovation - BayHelix Annual Meeting
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - BayHelix, a leading life sciences professional society for business leaders of Chinese origin, held its eighth annual conference in Shanghai April 10, and the day-long symposium trumpeted the opportunities for domestic pharma innovation brought on by China's healthcare reform and regulatory enhancements
You may also be interested in...
BeiGene CEO John Oyler On Building A Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
The CEO of one of China’s hottest start-ups sits down to talk about his strategy, the state of innovation in China and how to access funding from the Chinese government.
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.